New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
08:34 EDTCYTRCytRx says had positive meeting with FDA to discuss potential Phase 3 trial
The company announced that it has held a positive meeting with the FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. “We are planning to submit a special protocol assessment for the Phase 3 trial in patients with advanced soft tissue sarcomas,” said President and CEO Steven A. Kriegsman. “An agreement with the FDA with regards to an SPA would provide a clear regulatory pathway through the approval process. The initiation of a Phase 3 program for our lead drug candidate aldoxorubicin would represent a significant milestone in CytRx’s efforts to bring value to our stockholders and for those patients suffering from soft tissue sarcoma.”
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
10:10 EDTCYTRHigh option volume stocks
High option volume stocks: HNT THOR QRVO CYTR CBRL MAS CHKP TUP NXPI VEDL
July 21, 2015
10:14 EDTCYTRHigh option volume stocks:
Subscribe for More Information
09:21 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
08:47 EDTCYTRCytRx 9.1M share Spot Secondary priced at $2.75
Subscribe for More Information
July 20, 2015
19:02 EDTCYTROn The Fly: After Hours Movers
Subscribe for More Information
16:02 EDTCYTRCytRx files to sell common stock, no amount given
Jefferies LLC is the sole book-running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use